Web Stats Provided By Google Analytics

Monday, April 28, 2014

SYLVANT Receives FDA Approval to Treat Multicentric Castleman's Disease

SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced interleukin-6 in a nonclinical study.

http://ift.tt/1mQwHuz
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)